<DOC>
	<DOCNO>NCT00000861</DOCNO>
	<brief_summary>The purpose study evaluate effect immediate versus defer indinavir ( IDV ) addition background therapy disease progression death patient CD4+ cell count 200 500 cells/mm3 plasma HIV RNA level &gt; = 10,000 copies/ml . This study aim examine two management strategy , immediate versus defer IDV therapy , clinical effect context background antiretroviral ( AR ) therapy , give accord current clinical practice . There urgent need identify optimal use IDV patient management , since clinical endpoint study complete United States . Since little information long term durability clinical effect , even less information timing initiation protease inhibitor therapy , explore disease progression survival impact immediate versus delay use IDV yield important information guide clinical decision make group patient .</brief_summary>
	<brief_title>The Addition Indinavir Anti-HIV Treatment HIV-Infected Patients</brief_title>
	<detailed_description>This study aim examine two management strategy , immediate versus defer IDV therapy , clinical effect context background antiretroviral ( AR ) therapy , give accord current clinical practice . There urgent need identify optimal use IDV patient management , since clinical endpoint study complete United States . Since little information long term durability clinical effect , even less information timing initiation protease inhibitor therapy , explore disease progression survival impact immediate versus delay use IDV yield important information guide clinical decision make group patient . Prior randomization patient clinician determine whether background therapy zidovudine ( ZDV ) plus lamivudine ( 3TC ) background antiretroviral therapy ( OBAT ) . Patients randomize IDV match placebo . AS PER AMENDMENT 06/27/97 : The protocol close 03/25/97 , patient unblinded assigned treatment . Patients still study medication eligible protocol extension . Patients randomized immediate IDV may continue therapy additional 4 month . All study therapy , immediate delay therapy , must discontinue 10/24/97 .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Indinavir</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Topical and/or antifungal agent , except ketoconazole . Treatment , maintenance , chemoprophylaxis approve agent OIs give clinically indicate . Clinically indicated antibiotic , unless exclude . Systemic corticosteroid use &lt; 21 day acute problem permit clinically indicate . However , chronic systemic corticosteroid use avoid . Recombinant erythropoietin ( rEPO ) granulocytecolony stimulate factor ( GCSF , filgrastim ) . Didanosine ( ddI ) . Regularly prescribed medication , antipyretic , antidepressant , oral contraceptive , megestrol acetate , testosterone , medication . Patients must : A work diagnosis HIV infection . A CD4+ count 200 500 cells/mm3 . Signed , inform parental consent patient less 18 . NOTE : The DAIDS Clinical Science Research Committee ( CSRC ) deem protocol appropriate prisoner enrollment . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Febrile illness temperature &gt; 38.5 degree C ( 101.3 degree F ) within 3 day prior study entry . Concurrent Medication : Excluded : Nonnucleoside reverse transcriptase inhibitor . Protease inhibitor except IDV . Rifabutin rifampin . Ketoconazole . Terfenadine , astemizole , cisapride , triazolam midazolam . Patients follow prior condition exclude : History prior saquinavir ( SQV ) therapy 14 day . History prior protease inhibitor therapy SQV . History serious opportunistic infection .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Drug Administration Schedule</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>CD4 Lymphocyte Count</keyword>
	<keyword>Indinavir</keyword>
	<keyword>RNA , Viral</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Viral Load</keyword>
</DOC>